subvenite lamotrigine 150 mg
1 INDICATIONS AND USAGE SUBVENITE is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of SUBVENITE in the acute treatment of mood episodes has not been established. 1.1 Epilepsy Adjunctive Therapy SUBVENITE is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic (PGTC) seizures. generalized seizures of Lennox-Gastaut syndrome. Monotherapy SUBVENITE is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of SUBVENITE have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder SUBVENITE is indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy [see Clinical Studies ( 14.2 )] . Limitations of Use Treatment of acute manic or mixed episodes is not recommended. Effectiveness of SUBVENITE in the acute treatment of mood episodes has not been established.
owp pharmaceuticals, inc.
ROUND WHITE 15LA
15LA ROUND WHITE
Related Pills
subvenite lamotrigine 100 mg
owp pharmaceuticals, inc.
subvenite lamotrigine 25 mg
owp pharmaceuticals, inc.
lamotrigine 200 mg
owp pharmaceuticals, inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING SUBVENITE (
LAMOTRIGINE) tablets, USP 25 mg white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “2L” on one side and break line on other side. Bottle of 100 NDC-69102-301-01 Bottle of 6600 NDC-69102-301-02 SUBVENITE (
LAMOTRIGINE) tablets, USP 100 mg white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “10LA” on one side and break line on other side. Bottle of 100 NDC-69102-319-01 Bottle of 2500 NDC-69102-319-02 SUBVENITE (
LAMOTRIGINE) tablets, USP 150 mg white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “15LA” on one side and break line on other side. Bottle of 100 NDC-69102-150-06 SUBVENITE (
LAMOTRIGINE) tablets, USP 200 mg white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “20LA” on one side and break line on other side. Bottle of 100 NDC-69102-320-01 SUBVENITE (
LAMOTRIGINE) tablets, USP Starter Kit for Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Valproate (orange Kit). 25 mg, white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “2L” on one side and break line on other side. 100 mg, white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “10LA” on one side and break line on other side. Blister pack of 42, 25 mg tablets and 7, 100 mg tablets NDC-69102-300-01 SUBVENITE (
LAMOTRIGINE) tablets, USP Starter Kit for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, or Primidone and Not Taking Valproate (green Kit). 25 mg, white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “2L” on one side and break line on other side. 100 mg, white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “10LA” on one side and break line on other side. Blister pack of 84, 25 mg tablets and 14, 100 mg tablets NDC-69102-312-01 SUBVENITE (
LAMOTRIGINE) tablets, USP Starter Kit for Patients Taking Valproate (blue Kit). 25 mg, white to off white, round shape, flat face beveled edge, uncoated tablets debossed with “2L” on one side and break line on other side. Blister pack of 35 tablets NDC-69102-306-01 Storage Store at 20° to 25° C (68° to 77° F); excursions permitted to 15° to 30° C (59° to 86° F) [See USP Controlled Room Temperature]
More pills like ROUND 15LA